2018 International Congress » Clinical Trials and Therapy in Movement Disorders

Date: Saturday, October 6, 2018

Time: 1:45pm-3:15pm

Location: Hall 3FG

Meeting: 2018 International Congress

1:45pm-3:15pm: A case of early onset parkinsonism caused by PLA2G6 gene mutation

L. Chen, S. Xu (Guangdong, China)

1:45pm-3:15pm: A German-Austrian multicenter, non-interventional, prospective study for the treatment with abobotulinumtoxinA injections in naïve and previously treated patients suffering from cervical dystonia

W. Jost, A. Schramm, M. Müngersdorf, A. Stenner, P. Schwingenschuh, P. Maisonobe, M. Koch, B. Haslinger (Wolfach, Germany)

1:45pm-3:15pm: A Phase 2 Efficacy Study of CX-8998, a Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose-Selection Rationale

S. Papapetropoulos, M. Lee, S. Boyer, M. Versavel (Cambridge, MA, USA)

1:45pm-3:15pm: A Preliminary Study of Cinnamomum verum on Anxiety, Locomotor Activity and Emotionality Behaviour in Wistar Albino Rats

N. Ahmed (Aligarh, India)

1:45pm-3:15pm: Advanced Parkinson’s disease Diagnosis and Treatment Trends in Israel – Sub-Analysis of the OBSERVE-PD Multi-Country, Cross-Sectional Study

R. Djaldetti, S. Hassin-Baer, M. Anca-Herschkovitsch, R. Gross, R. Cohen, H. Banayan, K. Onuk, T. Gurevich (Petah Tikva, Israel)

1:45pm-3:15pm: Alleviation of freezing of gait in patients with Parkinson’s disease by high-frequency rTMS over SMA is associated with normalization of brain connectivity patterns

T.M. Mi, S. Garg, F. Ba, T. Wu, P.P. Liang, L.L. Gao, K.C. Li, P. Chan, M. McKeown (Beijing, China)

1:45pm-3:15pm: Ankle proprioception and postural instability in Parkinson’s disease

H. Teasdale, E. Preston, W. Spratford, G. Waddington (Bruce, Australia)

1:45pm-3:15pm: Background: Transcranial magnetic stimulation (rTMS) may influence the progression of PD

J. Málly (Sopron, Hungary)

1:45pm-3:15pm: Bipolar directional DBS in VIM-stimulated patients

J. Steffen, P. Reker, F. Mennicken, T. Dembek, H. Dafsari, G. Fink, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)

1:45pm-3:15pm: Botulinum toxin in Essential Hand Tremor – A Randomized Double-Blind Placebo-Controlled study with Customized Injection Approach

S. Mittal, D. Machado, D. Richardson, D. Dubey, B. Jabbari (Bangalore, India)

1:45pm-3:15pm: Clinical study on the correlation between Parkinson’s somatosensory evoked potentials and STN-DBS parameters

Z. Jing, Y. Xiaoxue, G. Shuzhao, S. Chunli, L. Zhanhua, (Dalian, China)

1:45pm-3:15pm: Comparison of virtual-reality-gaming and activity-based gait and balance training on gait, balance and quality of life in patients with Parkinson’s disease

A. Ogundele, M. Olaogun, M. Komolafe (Ile-Ife, Nigeria)

1:45pm-3:15pm: Deep brain stimulation (DBS) for dyskinetic cerebral palsy: A pilot study

S. Duma, N. Mahant, A. Ha, S. Kim, A. Phu, K. Stewart, M-C. Waugh, N. Wolfe, D. Russell, B. Owler, M. Krause, V. Fung (Westmead, Australia)

1:45pm-3:15pm: Design and Status of the BIIB054 SPARK Trial

Parkinson Study Group, A. Siderowf (NY, USA)

1:45pm-3:15pm: Development of evidence-based clinical practice guideline (CPG) of complementary and alternative medicine (CAM) for Parkinson’s disease (PD)

K.H. Cho, S.W. Kwon, S.H. Lee, T.H. Kim (Seoul, Republic of Korea)

1:45pm-3:15pm: Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study

J. Cedarbaum, K. Evans, M. Yang, J. Xiao (Cambridge, MA, USA)

1:45pm-3:15pm: Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease

C. Kutz, L. Adams, E. Moncheski (Colorado Springs, CO, USA)

1:45pm-3:15pm: Efficacy of zonisamide on motor symptoms in dementia with Lewy bodies: A post-hoc analysis of a phase 3 study

H. Maruyama, M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, K. Kosaka (Tokyo, Japan)

1:45pm-3:15pm: Feasibility and Efficacy of Brainstem Modulation Therapy for the Management of Parkinson’s Disease

K. Ade, A. Podlewska, T. Pellet-Higgins, S. Banducci, M. Bodani, M. Sakel, D. Wilkinson (Raleigh, NC, USA)

1:45pm-3:15pm: Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

1:45pm-3:15pm: Improvements of tremor control and life quality of refractory essential tremor patients after MR-guided focused ultrasound thalamotomy – A Taiwan experience

H.C. Lai, K. Tsai, W.C. Chang, T. Taira, C.Y. Wei (Changhua County, Taiwan)

1:45pm-3:15pm: Intraoperative local field potential recordings from deep brain stimulation electrodes help predict efficacy of subthalamic nucleus stimulation in patients with Parkinson’s disease

C. Chen, M. Liu, H. Chan, P. Tu, C. Lu, P. Brown (Taoyuan City, Taiwan)

1:45pm-3:15pm: INTREPID: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson’s disease

J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

1:45pm-3:15pm: Levodopa effect on non-motor symptoms in late stage Parkinson’s disease

K. Rosqvist, P. Odin, P. Hagell, S. Iwarsson, M. Nilsson, A. Storch (Lund, Sweden)

1:45pm-3:15pm: Linking neuroplastic effects to behavioral changes after balance training in Parkinson’s disease: a study protocol of a randomized controlled trial

E. Franzén, H. Johansson, M. Freidle, U. Ekman, E. Schalling, A. Lebedev, M. Lövdén, S. Holmin, P. Svenningsson, M. Hagströmer (Huddinge, Sweden)

1:45pm-3:15pm: Low-Fat Versus Ketogenic Diet In Parkinson’s Disease: A Pilot Randomized Controlled Trial

M. Phillips, D. Murtagh, L. Gilbertson, F. Asztely, C. Lynch (Hamilton, New Zealand)

1:45pm-3:15pm: Neuroprotective role of Tinospora cordifolia in MPTP induced Parkinsonian mouse model

S. Singh, H. Birla, S. Rai, W. Zahra, S. Singh (Varanasi, India)

1:45pm-3:15pm: Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis

T. Dam, L. Zhang, I. Qureshi, M. Grundman, G. Tirucherai, C. Bechtold, M. Ahlijanian, L. Golbe, L. Honig, S. Isaacson, M. Grossman, N. McFarland, I. Litvan, D. Geldmacher, T. Xie, Y. Bordelon, P. Tuite, P. O’Suilleabhain, T. Zesiewicz, B. Han, A. Boxer (Cambridge, MA, USA)

1:45pm-3:15pm: PASSPORT, An Ongoing Phase 2 Study in Patients with PSP– Baseline Characteristics

T. Dam, A. Boxer, L. Golbe, G. Höglinger, H. Morris, I. Litvan, J.C. Corvol, A. Lang, C. Bechtold, I. Qureshi, M. Grundman, B. Han, J. O'Gorman, T. Olsson, S. Budd Haeberlein (Cambridge, MA, USA)

1:45pm-3:15pm: PPMI driven sample size estimation for clinical trials in Parkinson’s disease

K. Marek, J. Seibyl, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, K. Kieburtz, C. Tanner, L. Chahine, A. Siderowf, T. Simuni (New Haven, CT, USA)

1:45pm-3:15pm: Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

1:45pm-3:15pm: Relationship between non-motor symptom symptoms and clinical symptoms in Parkinson’s disease using “Non-Motor Symptom assessment scale for Parkinson’s disease”

T. Matsubara, K. Suzuki, H. Fujita, M. Matsubara, A. Numao, H. Sakuramoto, Y. Watanabe, T. Kadowaki, K. Hirata (Tochigi, Japan)

1:45pm-3:15pm: Safinamide in Parkinson’s disease

G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

1:45pm-3:15pm: Single limb stance test performance – Difference between tremor dominant and akinetic rigid dominant parkinson’s disease – A pilot study

S. Durairaj, A. Christina, V. Mathew, M. Gowri (Vellore, India)

1:45pm-3:15pm: Specific active immunotherapy (SAIT) against alpha-synuclein with AFFITOPE® PD01A and PD03A: Results from the AFF009 phase I trial

W. Meissner, A. Pavy-Le Traon, A. Foubert-Samier, M. Galitzky, B. Laurens, U. Sabatini, S. Schmidhuber, D. Winter, G. Galabova, G. Staffler, A. Schneeberger, A. Kutzelnigg, O. Rascol (Bordeaux Cedex, France)

1:45pm-3:15pm: STN deep brain stimulation can directly suppress levodopa-induced dyskinesia in Parkinson’s disease

J. Li, Y. Zhang (Beijing, China)

1:45pm-3:15pm: The effects of Nordic walking on gait functions in people with Parkinson’s disease: A long-term pilot study

M. Mak, I. Wong-Yu (Hong Kong, Hong Kong)

1:45pm-3:15pm: The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a Novel Primary Efficacy Outcome in Patients with Pantothenate Kinase-Associated Neurodegeneration

F. Greblikas, M. Escolar, T. Klopstock, R. Marshall, B. Perez, S. Tuller, A. Videnovic (San Diego, CA, USA)

1:45pm-3:15pm: The PDSAFE falls prevention programe for people with Parkinson’s: A multicentre randomised controlled trial

A. Ashburn, R. Pickering, L. Rochester, H. Roberts, C. Ballinger, S. Hulbert, I. Marian, C. Fitton, E. McIntosh, V. Goodwin, A. Nieuwboer, S. Lamb, K. Chivers Seymour (Southampton, United Kingdom)

1:45pm-3:15pm: The Research of the Structural Changes of Cerebellar Tissue in Tremor-type Parkinson’s Disease Based on DKI

T. Siyu, T. Dan, X. xiaoyan, Q. Jin, H. Xiushuang (Dalian, China)

1:45pm-3:15pm: Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist in development for Essential Tremor and Parkinson’s disease Tremor in Cav3 driven neurological models

M. Lee, E. Newbold, S. Papapetropoulos (Cambridge, MA, USA)

1:45pm-3:15pm: Zonisamide improves parkinsonism in DLB patients: A randomized phase 3 trial

M. Murata, T. Odawara, K. Hasegawa, R. Kajiwara, H. Takeuchi, M. Tagawa, K. Kosaka (Kodaira, Japan)

« View all sessions from the 2018 International Congress.